TY - JOUR
AU1 - Celli, M
AU2 - De Giorgi, U
AU3 - Caroli, P
AU4 - Di Iorio, V
AU5 - Fantini, L
AU6 - Rossetti, V
AU7 - Foca, F
AU8 - Nicolini, S
AU9 - Giganti, M
AU1 - Paganelli, G
AU1 - Matteucci, F
AB - PurposeTo evaluate the clinical value of 68Ga-PSMA PET/CT negativity in patients with biochemical recurrent prostate cancer (BCR).MethodsOne hundred three BCR patients (median age, 70 years; median PSA, 0.47 ng/mL) with negative 68Ga-PSMA PET/CT, followed up for at least 1 year, were retrospectively identified in a database of 1003 consecutive patients undergoing 68Ga-PSMA PET/CT for BCR. Clinical recurrence (CR) was determined or excluded on follow-up imaging selected as per clinical practice. Clinical recurrence-free survival (CRFS) was computed from the date of negative 68Ga-PSMA PET/CT to the date of evident disease; frequencies of CRFS were described as per ISUP patient subset (subset 1: ISUP grades 1 and 2; subset 2: ISUP grade 3; subset 3: ISUP grades 4 and 5) and other conventional variables.ResultsIn 57 patients out of 103 (55.3%), CR was detected in the prostatic fossa (45.6%), nodes (38.6%), and bone (15.8%). The median CRFS was 15.4 months (range, 12.1–20.5), with a CRFS at 12 months in 61.4% of cases (range, 50.9–70.4) whereas the 24-month CRFS was 34.8% (range, 24–45.8). ISUP subset 1 benefited from significantly longer CRFS compared to subset 2 and subset 3 (median CRFS, 20.5 months, 12.6 months, and 12.1 months, respectively). ISUP subset 3 had significantly poorer 24-month CRFS (9.3%) compared to subset 1 (47.8%) and subset 2 (33.5%). At the univariate and multivariate analyses, the ISUP subset was the only significant risk factor for clinical relapse; ISUP subset 3 and subset 2 patients held a higher risk of CR compared to subset 1 patients (HR of 2.75 [1.35–5.57] for subset 3 versus subset 1; HR of 2.08 [1.11–3.88] for subset 2 versus subset 1).Conclusion68Ga-PSMA PET/CT negativity in early BCR patients (PSA < 0.5 ng/mL) with low-grade primary prostate cancer (ISUP1 and 2) may support the exploration of a clinical surveillance approach in future prospective studies.
TI - Clinical value of negative 68Ga-PSMA PET/CT in the management of biochemical recurrent prostate cancer patients
JF - European Journal of Nuclear Medicine and Molecular Imaging
DO - 10.1007/s00259-020-04914-8
DA - 2020-06-26
UR - https://www.deepdyve.com/lp/springer-journals/clinical-value-of-negative-68ga-psma-pet-ct-in-the-management-of-kh4KsZxx8V
SP - 87
EP - 94
VL - 48
IS - 1
DP - DeepDyve
ER -